Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma.
Journal: 2007/June - Croatian Medical Journal
ISSN: 1332-8166
PUBMED: 17436385
Abstract:
OBJECTIVE
To analyze genetic alterations of p53 gene in Slovenian gastric cancer patients and to compare these alterations with clinicopathological parameters in order to assess the value of p53 as a prognostic factor.
METHODS
We analyzed the samples from 230 Slovenian patients with gastric cancer, collected between 1983 and 2001. p53 expression was evaluated immunohistochemically with DO-7 monoclonal antibody. In addition, loss of heterozigosity (LOH) and microsatellite instability (MSI) of p53 gene were evaluated, as well as its mutational status in the selected population of patients.
RESULTS
p53 expression was associated with poorer survival and it was an independent predictor in multivariate analysis, along with TNM (T--size of tumor, N--nodal involvement, M--distant metastasis) stage status. Loss of heterozigosity and microsatellite instability status did not influence survival, however we found association of loss of heterozigosity with Lauren's (Mantel-Haenszel test, P=0.004) and Ming's (Mantel-Haenszel test, P<0.001) classification, whereas microsatellite instability was associated with gender (Mantel-Haenszel test, P=0.017), TNM stage (chi(2) test, P=0.006) of gastric cancer, and lymph node involvement (pN) (chi(2) test, P=0.004). Conclusions. The data on p53 abnormalities, when considered separately, could be of relative value for predicting the behavior of gastric tumors. However, our analyses showed that studying p53 overexpression, loss of heterozigosity, microsatellite instability, and mutational analysis could provide data that, particularly in combination with some clinicopathological features, might be of clinical value for predicting the tumor behavior and patient response to therapy.
Relations:
Content
Citations
(4)
References
(33)
Diseases
(1)
Conditions
(1)
Genes
(1)
Organisms
(1)
Processes
(3)
Similar articles
Articles by the same authors
Discussion board
Croat Med J 48(2): 207-217

Significance of Genetic Abnormalities of p53 Protein in Slovenian Patients with Gastric Carcinoma

Clinical Department for Abdominal Surgery, University Clinical Center, Ljubljana, Slovenia
Faculty of Medicine, Institute of Biochemistry, Medical Center for Molecular Biology, Ljubljana, Slovenia
Institute of Oncology, Department of Pathology, Ljubljana, Slovenia
Correspondence to:
Radovan Komel
Faculty of Medicine, Institute of Biochemistry
Medical Center for Molecular Biology
Vrazov trg 2, SI-1000 Ljubljana, Slovenia
is.jl-inu.fm@lemok.navodar
Received 2006 Oct 12; Accepted 2007 Mar 19.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim

To analyze genetic alterations of p53 gene in Slovenian gastric cancer patients and to compare these alterations with clinicopathological parameters in order to assess the value of p53 as a prognostic factor.

Methods

We analyzed the samples from 230 Slovenian patients with gastric cancer, collected between 1983 and 2001. p53 expression was evaluated immunohistochemically with DO-7 monoclonal antibody. In addition, loss of heterozigosity (LOH) and microsatellite instability (MSI) of p53 gene were evaluated, as well as its mutational status in the selected population of patients.

Results

p53 expression was associated with poorer survival and it was an independent predictor in multivariate analysis, along with TNM (T – size of tumor, N – nodal involvement, M – distant metastasis) stage status. Loss of heterozigosity and microsatellite instability status did not influence survival, however we found association of loss of heterozigosity with Lauren’s (Mantel-Haenszel test, P = .004) and Ming’s (Mantel-Haenszel test, P<.001) classification, whereas microsatellite instability was associated with gender (Mantel-Haenszel test, P = .017), TNM stage (χ test, P = .006) of gastric cancer, and lymph node involvement (pN) (χ test, P = .004).

Conclusions

The data on p53 abnormalities, when considered separately, could be of relative value for predicting the behavior of gastric tumors. However, our analyses showed that studying p53 overexpression, loss of heterozigosity, microsatellite instability, and mutational analysis could provide data that, particularly in combination with some clinicopathological features, might be of clinical value for predicting the tumor behavior and patient response to therapy.

Abstract

In the 1980s, stomach cancer was the most frequent type of cancer worldwide and, although its incidence has gradually declined in developed countries, it still remains one of the leading causes of mortality worldwide, with a modest 5-year survival of about 25% (1,2). In general, it is still the one of the leading cause of cancer-related death, surpassed only by lung and breast cancer (3,4).

According to the classification by Lauren (5), stomach cancer is classified into two main histological types: diffuse and intestinal. Particular combinations of genetic and epigenetic changes differ in both subtypes, although a few of them appear to be common, as shown by several studies in the last decade (6-8). Namely, a significant proportion of intestinal type carcinomas progress to diffuse types, and in individuals a large number of tumors could also be comprised of a mixture of both cellular subtypes (9,10). In addition to hypermethylation of several genes and loss of heterozigosity, abnormalities of p53 tumor suppressor gene are the most evident genetic changes found in both types of gastric cancer, which is in accordance with generally accepted opinion that genetic changes of p53 are one of the most prevalent alterations in human cancers (8,10,11). The main mechanisms of inactivation in gastric cancer are loss of heterozigosity, mutations, and frame shift deletions (8,9). These abnormalities occur in 46.6 to 74% of gastric cancers, regardless of the histological subtype. They are also frequently observed in pre-cancerous lesions such as intestinal metaplasia and dysplasia, which are precursors of the intestinal type of gastric cancer (9,12).

Most mutations of p53 gene or genetic and/or epigenetic changes of upstream and/or downstream located genes in the p53 network result in a loss of function of the wild-type gene product. However, most but not all mutant p53 proteins have a prolonged half-life and accumulate in cells (13,14). Both p53 accumulation and its absence in the nucleus of malignant cells could thus be used as a valuable prognostic marker and predictor of clinical outcome of gastric tumors. Namely, several studies have shown the association of p53 mutations with particular histological type of gastric cancer, age of the patients at the onset of malignancies, and poor response to the treatment (9,14-16).

In the present study, we studied a series of 230 gastric carcinomas, collected in a period from 1983 to 2001. We wanted to combine molecular genetic analysis data on p53, such as expression, loss of heterozygosity (LOH), microsatellite instability (MSI), and mutational status with tumor descriptive characteristics in order to discern the value of p53 as a molecular marker for diagnosis and/or prognosis in this type of cancer. We showed that at least one of the selected clinical or histopathological features might be associated with genetic variables such as p53 expression, loss of heterozigosity, or microsatellite instability, and could thus in combination improve the determination of biological feature and/or prognosis of gastric malignancy.

Acknowledgments

This work was supported by the grant No. P1-0104 (Functional Genomics and Biotechnology for Health) from Slovenian Research Agency. The authors also are grateful to Professor Janez Stare from Institute for Biomedical Informatics (IBMI) at the Faculty of Medicine, University of Ljubljana for checking the statistical presentation of the data in the manuscript.

Acknowledgments

References

  • 1. Bacani J, Zwingerman R, Di Nicola N, Spencer S, Wegrynowski T, Mitchell K, et al Tumor microsatellite instability in early onset gastric cancer. J Mol Diagn. 2005;7:465–77.[Google Scholar]
  • 2. Wu CW, Chi CW, Lin WCGastric cancer: prognostic and diagnostic advances. Expert Rev Mol Med. 20022002:1–12.[PubMed][Google Scholar]
  • 3. Crew KD, Neugut AIEpidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.[Google Scholar]
  • 4. Ferlay J, Bray F, Pisani P, Parkin D. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2001. [PubMed]
  • 5. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.[PubMed]
  • 6. Tahara E, Kuniyasu H, Yasui W, Yokozaki HGene alterations in intestinal metaplasia and gastric cancer. Eur J Gastroenterol Hepatol. 1994;6(Suppl 1):S97–102.[PubMed][Google Scholar]
  • 7. Kountouras J, Zavos C, Chatzopoulos DNew concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology. 2005;52:1305–12.[PubMed][Google Scholar]
  • 8. Tahara EGenetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;(157):327–49.[PubMed][Google Scholar]
  • 9. Smith MG, Hold GL, Tahara E, El-Omar EMCellular and molecular aspects of gastric cancer. World J Gastroenterol. 2006;12:2979–90.[Google Scholar]
  • 10. Tamura GAlterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006;12:192–8.[Google Scholar]
  • 11. Yokozaki H, Yasui W, Tahara EGenetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49–95.[PubMed][Google Scholar]
  • 12. Kufe DW, Pollock RE, Wichselbaum RR, Bast RC, Gansler TS, Holland JF, et al, editors. Cancer medicine. 6th ed. Hamilton, Ontario: BC Decker; 2003. [PubMed]
  • 13. Shiao YH, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, et al Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev. 2000;9:631–3.[PubMed][Google Scholar]
  • 14. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger ATP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258–70.[PubMed][Google Scholar]
  • 15. Gottlieb TM, Oren Mp53 in growth control and neoplasia. Biochim Biophys Acta. 1996;1287:77–102.[PubMed][Google Scholar]
  • 16. Levine AJ, Hu W, Feng ZThe P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13:1027–36.[PubMed][Google Scholar]
  • 17. Borrmann R. Geshwulste des Magens und Duodenums. In: Henkie F, Lubarsch O, editors. Handbuch der Speziellen Pathologischen Anatomie und Histologie. Berlin, Springer-Verlag, 1926:865. [PubMed]
  • 18. Ming SCCellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer. 1998;1:31–50.[PubMed][Google Scholar]
  • 19. Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, et al CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis. 2002;23:419–24.[PubMed][Google Scholar]
  • 20. Cawkwell L, Lewis FA, Quirke PFrequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer. 1994;70:813–8.[Google Scholar]
  • 21. Soussi T, Beroud CAssessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233–40.[PubMed][Google Scholar]
  • 22. Hudler P, Vouk K, Liovic M, Repse S, Juvan R, Komel RMutations in the hMLH1 gene in Slovenian patients with gastric carcinoma. Clin Genet. 2004;65:405–11.[PubMed][Google Scholar]
  • 23. Chang SC, Lin JK, Lin TC, Liang WYGenetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol. 2005;26:65–75.[PubMed][Google Scholar]
  • 24. Zheng L, Wang L, Ajani J, Xie KMolecular basis of gastric cancer development and progression. Gastric Cancer. 2004;7:61–77.[PubMed][Google Scholar]
  • 25. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006;17(suppl_7):vii97–vii102.[PubMed][Google Scholar]
  • 26. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 2003;63:3309–16.[PubMed][Google Scholar]
  • 27. Bataille F, Rummele P, Dietmaier W, Gaag D, Klebl F, Reichle A, et al Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol. 2003;56:286–92.[Google Scholar]
  • 28. Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, et al Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol. 2003;33:173–9.[PubMed][Google Scholar]
  • 29. Muller W, Borchard FPrognostic influence of p53 expression in gastric cancer. J Pathol. 1996;178:255–8.[PubMed][Google Scholar]
  • 30. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17:1364–74.[PubMed][Google Scholar]
  • 31. Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, et al Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res. 2000;6:4782–8.[PubMed][Google Scholar]
  • 32. Sul J, Yu GP, Lu QY, Lu ML, Setiawan VW, Wang MR, et al P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett. 2006;238:210–23.[Google Scholar]
  • 33. Soussi T, Ishioka C, Claustres M, Beroud CLocus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer. 2006;6:83–90.[PubMed][Google Scholar]
  • 34. Sugiyama H, Arita M, Min Z, Zhong X, Iwasaki I, Hirano K, et al A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW. Tohoku J Exp Med. 2003;201:229–37.[PubMed][Google Scholar]
  • 35. Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, et al Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int. 2001;51:440–4.[PubMed][Google Scholar]
  • 36. Pinto-de-Sousa J, Silva F, David L, Leitao D, Seixas M, Pimenta A, et al Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology. 2004;44:323–31.[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.